Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Gilotrif

- PMLiVE

Gilead and MacroGenics enter $1.7bn oncology partnership

The collaboration will focus on developing bispecific antibodies

- PMLiVE

Tavros Therapeutics and Vividion Therapeutics collaborate in oncology programmes

Tavros will receive $17.5m in a cash upfront payment from Vividion, according to the deal

- PMLiVE

Pfizer’s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

An improvement in radiographic progression-free survival was demonstrated

- PMLiVE

Boehringer Ingelheim and HeartBeat.bio partner to accelerate heart disease treatments

Heart and circulatory diseases cause over 160,000 deaths in the UK each year

Overcoming Patient Recruitment Challenges in Rare Disease Trials

Rare diseases are thought to affect up to 446 million people worldwide. With more than 7,000 rare diseases, most of which are genetic, it’s vital all patients can access new...

Innovative Trials

- PMLiVE

The immunotherapy knowledge gap: keeping the patient at the heart of cancer treatment

Advances in cancer treatment are frequent, but how much do we actually understand about these new treatments?

Say Communications

- PMLiVE

AstraZeneca’s Tezspire receives MHRA approval as add-on treatment for severe asthma

Tezspire demonstrated reduced annualised rate of asthma exacerbations

- PMLiVE

Roche announces launch of HPV self-sampling solution for cervical cancer screening

Around 342,000 die from cervical cancer worldwide, despite it being a preventable disease

- PMLiVE

AstraZeneca’s Tezspire receives EC approval as severe asthma add-on treatment

Tezspire demonstrated superiority across every primary and key secondary endpoint compared to placebo

- PMLiVE

Lilly’s Retevmo approved by FDA for RET fusion+ advanced/metastatic solid tumours

Results demonstrated an overall response rate of 44% across multiple tumour types

- PMLiVE

University of Cambridge launches Early Cancer Institute for complex cancers

It is the first UK institute dedicated to identifying and researching early cancers

- PMLiVE

AstraZeneca’s COVID-19 treatment granted EC approval

Evusheld significantly reduced risk of severe COVID-19 or death in a phase 3 trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links